Immunomodulation therapy of diabetes by oral administration of a surfactin lipopeptide in NOD mice

• Published in: Vaccine 2014-11, Vol.32 (50), p.6812-6819
• Main Authors: Gao, Zhenqiu, Zhao, Xiuyun, Yang, Tao, Shang, Jun, Shang, Long, Mai, Haizhe, Qi, Gaofu
• Format: Article
• Language: English
• Subjects: Administration, Oral; Allergy and Immunology; Animals; Antigens; Applied microbiology; Atherosclerosis; Bacteria; Biological and medical sciences; Diabetes; Diabetes Mellitus, Type 1 - pathology; Diabetes Mellitus, Type 1 - prevention & control; Disease; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Fundamental and applied biological sciences. Psychology; Gram-positive bacteria; Heat shock proteins; Immune modulation; Immune response; Immune system; Immunoglobulin G - blood; Immunohistochemistry; Immunologic Factors - administration & dosage; Immunomodulation; Incidence; Insulin; Interleukin-10 - blood; Lipopeptides - administration & dosage; Lymphocytes; Mice, Inbred NOD; Microbiology; Peptides; Peptides, Cyclic - administration & dosage; Probiotics; Rodents; Software; Surfactin; Survival Analysis; T-Lymphocyte Subsets - immunology; Treatment Outcome; Tumor Necrosis Factor-alpha - blood; Type 1 diabetes mellitus; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2014.08.082

Highlights • Oral surfactin induces Tregs switching immune response from Th1- to Th2-type. • Tregs attenuates diabetes by secreting IL-10 and TGF-β to suppress activated CD8+ T cells. • Surfactin is a potential immunomodulator for immunotherapy of diabetes.